Alnylam Pharmaceuticals Inc (ALNY)vsCelularity Inc (CELU)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
CELU
Celularity Inc
$1.21
-4.72%
HEALTHCARE · Cap: $35.18M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 9053% more annual revenue ($3.71B vs $40.58M). ALNY leads profitability with a 8.5% profit margin vs -2.0%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
CELU
Avoid19
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for CELU.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
No standout strengths identified
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Smaller company, higher risk/reward
ROE of -63.7% — below average capital efficiency
Revenue declined 43.2%
Earnings declined 61.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : CELU
CELU has a balanced fundamental profile.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : CELU
The primary concerns for CELU are Market Cap, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while CELU is a turnaround play — different risk/reward profiles.
CELU carries more volatility with a beta of 0.79 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 19/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Celularity Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Celularity Inc. is a leading biotechnology firm focused on transforming the landscape of regenerative medicine through its unique therapeutic cellular products derived from the placenta. With a strong pipeline of next-generation immunotherapies, including allogeneic off-the-shelf solutions, the company aims to enhance treatment efficacy while reducing associated complications for cancer and other serious illnesses. Driven by an experienced leadership team and strategic partnerships, Celularity is well-positioned to address significant unmet medical needs, solidifying its role as a key player in the rapidly evolving field of advanced therapeutics.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?